JW Therapeutics Initiates Clinical Study for Carteyva in First-Line High-Risk Large B-Cell Lymphoma
China-based JW Therapeutics (HKG: 2126) has announced the initiation of a clinical study for its...
March 2023
Evaheart Med Raises USD 100 Million in Series A Funding Led by Sinovac
Chongqing Evaheart Medical Device Co., Ltd has reportedly raised close to USD 100 million in...
HQ Pharma and Shanxi HCXF Partner to Expand Oral Soluble Film R&D and Production
China-based firms HQ Pharma and Shanxi HCXF Pharmaceutical Co., Ltd have agreed to jointly expand...
Biocytogen and Janssen Sign Licensing Agreement for RenLite Platform
Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315) has announced the signing of a non-exclusive licensing...
Sumitomo Pharma Secures Rights to Vibegron for Asian Markets
Japan-based Sumitomo Pharma Co., Ltd has signed a sub-license deal with compatriot firm Kyorin Pharmaceutical...
Suzhou Porton Biologics Partners with Bennu Biotherapeutics for Gene and Cell Therapies
China-based contract development and manufacturing organization (CDMO) Suzhou Porton Biologics Ltd has entered into a...
Akeso Biopharma and Shanghai Pharmaceuticals Collaborate on Liposarcoma Treatment
China-based Akeso Biopharma (HKG: 9926) has announced a strategic collaboration agreement with compatriot firm Shanghai...
F-star Therapeutics’ Acquisition by invoX Pharma Cleared by CFIUS
UK biotech F-star Therapeutics, Inc. (NASDAQ: FSTX) has announced that it has received clearance from...
Biocytogen’s YH008 Gets NMPA Approval for Phase I Study
China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd has announced receiving approval from the China National Medical...
Heranova Closes $10M Seed Round for Women’s Health Solutions
Heranova Lifesciences Holding, a provider of women’s health solutions, has announced the successful closure of...
Inmagene’s Tavalisse First Prescribed in China for ITP Treatment
China-based Inmagene Biopharmaceuticals has announced that its in-licensed drug Tavalisse (fostamatinib) has been first prescribed...
AusperBio Initiates Phase I Trial for AHB-137 in New Zealand
Sino-US liver therapy developer AusperBio has announced the initiation of the first cohort dosing in...
China’s Party and State Institutions Reshuffle: Key Changes for Healthcare and Finance
The second plenary session of the 20th Communist Party of China (CPC) Central Committee has...
BrightGene’s Generic Halaven Approved for Marketing in China
China-based BrightGene Bio-Medical Technology Co., Ltd (SHA: 688166) has received marketing approval from the National...
Abcam and MEDx Expand Strategic Partnership on Claudin 18.2 Diagnosis
UK-based abcam (NASDAQ:ABCM) has announced a licensing agreement with China-headquartered MEDx Translational Medicine Co., Ltd,...
Inovio and ApolloBio Announce Positive Phase III Data for VGX-3100 Vaccine
US-based Inovio Pharmaceuticals (NASDAQ: INO) and China-based ApolloBio Corp. (NEEQ:430187) have announced positive data from...
Sunshine Medical Procurement Platform Announces VBP Tender Results for Yangtze River Delta
Shanghai’s Sunshine Medical Procurement All-In-One (SMPA) platform has revealed the resultant winning bids and spare...
Neo Modulus Secures Series B Funding for Regenerative Medical Device Development
Neo Modulus, a developer of regenerative implantable medical devices based in Suzhou, has reportedly raised...
Takeda’s Exkivity Receives First Prescription in China with Innovative Payment Solutions
Takeda Pharmaceutical Co., Ltd has announced the first prescription of its lung cancer therapy Exkivity...
Pudong New Area Grants Duty-Free Import Qualifications to Seven Companies
Seven companies have been awarded scientific and technological innovation duty-free import qualification designations by the...